Funding round brings in $33M for cholesterol drug developer

04/26/2013 | Xconomy

Esperion Therapeutics said it secured $33 million in a preferred stock funding round led by Longitude Capital and it will use the money to fund clinical trials. The Ann Arbor, Mich.-based firm is developing a cholesterol-lowering drug for patients who can't take statins. The drug, called ETC-1002, is in midstage development.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX